Pay in 4 interest-free payments of $31.50 Learn more
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9
is an inhibitor of epidermal growth factor (EGF) receptor kinase with an IC50 value of 460 µM in the human epidermoid carcinoma cell line A431
selective A2AR antagonist
displaced [3H]-rolipram from high-affinity rolipram binding sites and reversed xylazine/ketamine-induced anesthesia
InChi: InChI=1S/C15H11I4NO4/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23/h1-2
Pexidartinib hydrochloride
MDA 19 Size:Solid 10 mg is an inhibitor of epidermalMDA19 or MDA 19 is discontinued (DEA controlled substance). It is a selective agonist of the human peripheral cannabinoid (CB2) receptor, with an EC50 value for activation (63. 4 nM) that is 14 fold lower than that for central cannabinoid (CB1) activation (EC50 = 867 nM). MDA19 exhibited a distinctive in vitro functional profile at rat CB2 receptors and behaved as a CB1 CB2 agonist in vivo, characteristics of a protean agonist. MDA19 has potential for
US$ 1938.50
US$ 2045.00
US$ 161.00
US$ 251.00